Cosmo to Unveil First-of-its-Kind Clinical Study on the Use of GI Genius(TM) with Apple Vision Pro at Rush University Medical Center

Core Insights - Cosmo Pharmaceuticals is set to initiate a groundbreaking clinical usability study in July 2025, evaluating the integration of the GI Genius™ intelligent endoscopy module with Apple Vision Pro at Rush University Medical Center [1][4] - The study aims to assess the real-time application of this innovative technology during live colonoscopy procedures, marking a significant advancement in procedural medicine [2][5] Company Overview - Cosmo Pharmaceuticals N.V. focuses on developing innovative healthcare solutions, particularly in Healthtech/AI, dermatology, and gastroenterology [6][7] - The company has a strategic partnership with Medtronic, which has been the exclusive distributor of the GI Genius™ module since 2019 [5][7] Technology and Innovation - The software application designed for Apple Vision Pro allows physicians to visualize AI-generated insights from the GI Genius™ module without diverting their attention from the operative screen, potentially setting a new standard in GI endoscopy [2][3] - The GI Genius™ system enhances the adenoma detection rate (ADR) of colorectal polyps by up to 14.4%, showcasing its effectiveness in improving diagnostic outcomes [2] Clinical Significance - The upcoming usability study is the first of its kind and will involve patients undergoing routine colonoscopy, contributing to Cosmo's planned FDA submission following the study's conclusion [4] - The integration of AI and spatial computing in this context is expected to revolutionize procedural medicine by embedding real-time AI insights into the physician's workflow [5]